Market Cap (In USD)
2618.00
Revenue (In USD)
-
Net Income (In USD)
-
Avg. Volume
-
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1.0E-4-2.0E-4
- PE
- -
- EPS
- -
- Beta Value
- -123.117
- ISIN
- US03674U3005
- CUSIP
- 03674U300
- CIK
- 1316175
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. John Craig Thompson
- Employee Count
- -
- Website
- https://www.anthera.com
- Ipo Date
- 2010-03-01
- Details
- Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
More Stocks
-
DLPX
-
VARIMANVARIMAN GLOBAL ENTERPRISES LIM
VARIMAN
-
KAP
-
CCCHF
-
TOPCFTopcon Corporation
TOPCF
-
NSHRF
-
5102Guan Chong Berhad
5102
-
688101